Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has entered into a ...

Turnstone has engaged a financial advisor to assist in this process, and along with support from its other advisors, intends to explore potential strategic alternatives that may include, but are not ...

Lunit offers free AI biomarker services to SITC researchers for immuno-oncology studies Global researchers gain access to ...

SAN DIEGO - Turnstone Biologics Corp. (NASDAQ:TSBX), a clinical-stage biotechnology company with a market capitalization of $9.45 million, has announced the discontinuation of its TIDAL-01 clinical ...

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that ...

Researchers found that radiotherapy may reduce immune cells in the tumor-immune microenvironment, potentially impacting ...

Researchers identify glucose usage as one major divergence betweenT cells expanding in vitro versus those expanding in vivo.

Researchers have revolutionized cancer immunotherapy by developing a way to grow T cells in the lab that live longer and ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

Researchers from the University of Pittsburgh have developed a new way to grow T cells in the lab that enables them to live longer and better destroy cancer cells in a mouse model of melanoma compared ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Iovance Biotherapeutics (IOVA – Research Report), ...